SLC27A2 and neoplasm: The feasibility of this idea was recently demonstrated by restoring antigen presentation in a mouse model given the fatty acid metabolism inhibitor etomoxir [452], and not only the anti-tumor presentation of immune cells but also in another study, the research team also used the targeting of FATP2 to inhibit fatty acid accumulation in a mouse model to enhance the function of PD-L1, which achieved the therapeutic effect of tumor treatment [453].